1h Free Analyst Time
Dental Pain - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
This latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H2 2019, provides an overview of the Dental Pain (Central Nervous System) pipeline landscape.
A pain in the tooth is called dental pain. This can be caused by tooth decay, damaged filling, tooth fracture, etc. Symptoms of a toothache may include: tooth pain that may be sharp, throbbing, or constant. In some people, pain results only when pressure is applied to the tooth. Swelling around the tooth, fever or headache and foul-tasting drainage from the infected tooth occurs. Treatment for a toothache depends on the cause.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Dental Pain - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dental Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dental Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dental Pain (Toothache/Tooth Pain) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Discovery stages are 1, 2, 2 and 1 respectively.
Dental Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dental Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dental Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dental Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dental Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dental Pain (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dental Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dental Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionReport Coverage
Dental Pain (Toothache/Tooth Pain) - Overview
Dental Pain (Toothache/Tooth Pain) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Dental Pain (Toothache/Tooth Pain) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dental Pain (Toothache/Tooth Pain) - Companies Involved in Therapeutics Development
AfaSci Inc
Esteve Pharmaceuticals SA
Grunenthal GmbH
Nevakar Inc
Pacira BioSciences Inc
Promius Pharma LLC
Dental Pain (Toothache/Tooth Pain) - Drug Profiles
(celecoxib + tramadol hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diclofenac sodium + tramadol hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acetaminophen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AFAP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bupivacaine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFN-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dental Pain (Toothache/Tooth Pain) - Dormant Projects
Dental Pain (Toothache/Tooth Pain) - Discontinued Products
Dental Pain (Toothache/Tooth Pain) - Product Development Milestones
Featured News & Press Releases
Jun 26, 2019: New retrospective analysis shows EXPAREL associated with significantly less opioid use following third molar extraction
Sep 13, 2017: Pacira Pharmaceuticals, Aetna, and the American Association of Oral and Maxillofacial Surgeons join together in a program to reduce opioid exposure for patients undergoing wisdom tooth extraction
Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac
Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dental Pain (Toothache/Tooth Pain), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Dental Pain (Toothache/Tooth Pain) - Pipeline by AfaSci Inc, H2 2019
Dental Pain (Toothache/Tooth Pain) - Pipeline by Esteve Pharmaceuticals SA, H2 2019
Dental Pain (Toothache/Tooth Pain) - Pipeline by Grunenthal GmbH, H2 2019
Dental Pain (Toothache/Tooth Pain) - Pipeline by Nevakar Inc, H2 2019
Dental Pain (Toothache/Tooth Pain) - Pipeline by Pacira BioSciences Inc, H2 2019
Dental Pain (Toothache/Tooth Pain) - Pipeline by Promius Pharma LLC, H2 2019
Dental Pain (Toothache/Tooth Pain) - Dormant Projects, H2 2019
Dental Pain (Toothache/Tooth Pain) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Dental Pain (Toothache/Tooth Pain) - Discontinued Products, H2 2019
List of Figures
Number of Products under Development for Dental Pain (Toothache/Tooth Pain), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AfaSci Inc
- Esteve Pharmaceuticals SA
- Grunenthal GmbH
- Nevakar Inc
- Pacira BioSciences Inc
- Promius Pharma LLC
